Welcome to your Weekly Dose of Health Tech Innovation!
Stay ahead with the latest breakthroughs revolutionizing healthcare—from AI diagnostics to remote care solutions.
We bring you expert-curated insights, emerging trends, and must-know updates from the digital health frontier.
Whether you’re a clinician, innovator, or health tech enthusiast, this roundup delivers what matters most.
Let’s dive into the future of health, one innovation at a time.
Vektor Medical Appoints Kelly Perez as CFO and SVP of Operations
Vektor Medical, a medical technology company transforming cardiac arrhythmia care, announced the appointment of Kelly Perez as Chief Financial Officer (CFO) and Senior Vice President of Operations, strengthening its leadership team as adoption of vMap accelerates.
SimBioSys and Ricoh 3D Expand Access to TumorSight For Breast Cancer Surgery
SimBioSys, a clinical AI company that uses spatial biophysics to help make breast cancer treatments more precise, has signed a strategic, non-exclusive agreement with Ricoh 3D for Healthcare, LLC. Ricoh 3D for Healthcare is part of Ricoh USA, Inc. and makes FDA-approved, patient-specific medical devices both in central facilities and at the point of care. This partnership is meant to make TumorSight Viz, SimBioSys’s FDA-approved 3D surgical visualization tool for breast cancer surgery, more widely available.
Leal Therapeutics Raises $30Million for Neuro-Metabolic Therapies
Leal Therapeutics, a biotech company working on new treatments for disorders affecting the central nervous system, has raised $30 million in Series A funding. This investment is led by SV Health Investors’ Dementia Discovery Fund, with support from several other investors including OrbiMed, Newpath Partners, Chugai Venture Fund, Euclidean Capital, Alexandria Venture Investments, and PhiFund. This money will be used to move their main drug candidate, LTX-001, through clinical trials for schizophrenia. LTX-001 is an oral medication that can reach the brain and works by reducing excess glutamate, which is done by blocking an enzyme called glutaminase.
Zemcelpro Approved as First Cell Therapy Without Donor Match
ExCellThera Inc., along with its subsidiary Cordex Biologics, has been granted conditional marketing approval by the European Commission for Zemcelpro, making it the first cell therapy available for adults with blood cancers who do not have a suitable stem cell donor. This approval applies across all European Union member states, as well as Iceland, Norway, and Liechtenstein. Zemcelpro is developed from the same cord blood unit and includes two components: cryopreserved UM171-expanded CD34+ cells (dorocubicel) and unexpanded CD34– cells. Each year, more than 10,000 people in Europe are diagnosed with blood cancers such as leukemia and myelodysplastic syndromes that require stem cell transplants. However, many struggle to find a matched donor in time, particularly among underrepresented populations.
Longevity Research Boosted by Alamar Biosciences Deal
Human Longevity, Inc. (HLI), a well-known leader in precision health and longevity-centered care, has announced a new partnership with Alamar Biosciences, a company that specializes in precision proteomics. This collaboration is set to introduce new proteomic testing services that will increase scientific understanding of human aging and improve early detection of diseases.
Piedmont Atlanta Hospital Completes First Rare Liver-Heart Transplant
Piedmont Atlanta Hospital recently completed a rare combined liver and heart transplant, which is the first of its kind in Georgia in ten years and only the second adult dual transplant in the state. According to the United Network for Organ Sharing, fewer than 50 liver-heart transplants have been done in the southeastern U.S., showing how complex and uncommon this surgery is. Piedmont Atlanta is one of the busiest transplant centers in the country, ranking among the top ten for liver transplants and the top five for heart transplants based on the number of patients they treat.
Zydus Reports Positive Phase 2/3 Results for Saroglitazar Trial
Zydus Therapeutics, a wholly owned subsidiary of Zydus Lifesciences Ltd., a global innovation led healthcare company, announced positive topline results from the pivotal EPICS-III Phase 2(b)/3 clinical trial. In this trial, the safety and efficacy of Saroglitazar, an investigational alpha/gamma Peroxisome Proliferator-Activated Receptor (PPAR) agonist, was evaluated for the treatment of adult patients with Primary Biliary Cholangitis (PBC) who had an inadequate response or intolerance to ursodeoxycholic acid (UDCA), the current standard-of-care.
Novotech Backs Approval of Anlotinib Combination for Soft Tissue Sarcoma
Novotech, a globally recognized full-service clinical research organization (CRO), is proud to have partnered with Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ Pharma) in achieving a significant regulatory milestone: the approval of Anlotinib Hydrochloride Capsules for a new indication as a first-line treatment for unresectable locally advanced or metastatic soft tissue sarcoma (STS) in combination with chemotherapy. This approval marks the ninth indication for Anlotinib in China and represents the world’s first official approval of an Anlotinib-chemotherapy combination for first-line treatment of advanced or metastatic STS.
To share your insights, please write to us at sudipto@intentamplify.com
